Voyager Therapeutics, Inc.VYGREarnings & Financial Report
Voyager Therapeutics, Inc. is a clinical-stage biotechnology firm focused on developing AAV gene therapies for severe neurological diseases including Parkinson's, ALS, and rare monogenic CNS disorders. It operates mainly in the U.S., partnering with global biopharma companies to advance its treatment pipeline for underserved patient populations.
VYGR Q4 FY2025 Key Financial Metrics
Revenue
$15.3M
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
144.3%
Voyager Therapeutics, Inc. Q4 FY2025 Financial Summary
Voyager Therapeutics, Inc. reported revenue of $15.3M (up 144.3% YoY) for Q4 FY2025, with a net profit of N/A (up 20.5% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $15.3M |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Voyager Therapeutics, Inc. Annual Revenue by Year
Voyager Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $40.4M).
Voyager Therapeutics, Inc. Quarterly Revenue & Net Profit History
Voyager Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $15.3M | +144.3% | N/A | N/A |
| Q3 FY2025 | $13.4M | -45.7% | $-27.9M | -208.7% |
| Q2 FY2025 | $5.2M | -82.4% | $-33.4M | -642.0% |
| Q1 FY2025 | $6.5M | -66.8% | $-31.0M | -479.2% |
| Q4 FY2024 | $6.3M | -93.0% | N/A | N/A |
| Q3 FY2024 | $24.6M | +433.8% | $-9.0M | -36.7% |
| Q2 FY2024 | $29.6M | +509.5% | $-10.1M | -34.3% |
| Q1 FY2024 | $19.5M | -87.0% | $-11.3M | -58.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.5M | $29.6M | $24.6M | $6.3M | $6.5M | $5.2M | $13.4M | $15.3M |
| YoY Growth | -87.0% | 509.5% | 433.8% | -93.0% | -66.8% | -82.4% | -45.7% | 144.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $469.6M | $436.2M | $426.0M | $393.1M | $353.2M | $322.1M | $288.3M | $252.3M |
| Liabilities | $128.7M | $100.8M | $95.7M | $93.3M | $80.5M | $78.2M | $68.5M | $56.2M |
| Equity | $340.9M | $335.4M | $330.3M | $299.8M | $272.7M | $243.9M | $219.8M | $196.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $58.8M | $-31.6M | $-28.0M | $-15.3M | $-37.9M | $-33.3M | $-31.0M | $-132.5M |